{"id":70884,"date":"2026-07-29T18:33:08","date_gmt":"2026-07-29T10:33:08","guid":{"rendered":"https:\/\/flcube.com\/?p=70884"},"modified":"2026-07-29T18:33:08","modified_gmt":"2026-07-29T10:33:08","slug":"insilico-medicines-ai-discovered-pan-tead-inhibitor-ism6331-receives-fda-fast-track-designation-for-malignant-pleural-mesothelioma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70884","title":{"rendered":"Insilico Medicine&#8217;s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/3696:HKG\">HKG: 3696<\/a>) announced that <strong>ISM6331<\/strong>, a novel <strong>pan-TEAD inhibitor<\/strong> discovered through the company&#8217;s proprietary artificial intelligence platform, has received <strong>Fast Track Designation (FTD)<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for treating <strong>adult patients with unresectable malignant pleural mesothelioma<\/strong> who have progressed following anti-PD-1 antibody therapy and platinum-based chemotherapy.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Insilico Medicine (HKG: 3696)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>ISM6331<\/td><\/tr><tr><td><strong>Regulatory Agency<\/strong><\/td><td>U.S. Food and Drug Administration (FDA)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Fast Track Designation (FTD)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Unresectable malignant pleural mesothelioma (post anti-PD-1 \u00b1 anti-CTLA-4 + platinum chemo)<\/td><\/tr><tr><td><strong>Previous Designation<\/strong><\/td><td>Orphan Drug Designation (ODD) granted in 2024<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>29 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<h3 id=\"h-ai-driven-discovery\" class=\"wp-block-heading\">AI-Driven Discovery<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Origin:<\/strong> Discovered using Insilico&#8217;s proprietary <strong>AI drug discovery platform<\/strong><\/li>\n\n\n\n<li><strong>Structure Design:<\/strong> Novel <strong>non-covalent structure<\/strong> guided by <strong>Chemistry42&#8217;s structure-based drug design strategy<\/strong><\/li>\n\n\n\n<li><strong>Target Class:<\/strong> <strong>Pan-TEAD inhibitor<\/strong> \u2013 potential best-in-class candidate<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Currently in global multicenter Phase I trial (first patient dosed January 2025)<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-therapeutic-mechanism\" class=\"wp-block-heading\">Therapeutic Mechanism<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Primary Target:<\/strong> Tumors with <strong>Hippo pathway abnormalities<\/strong><\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Demonstrates <strong>synergistic anti-tumor effects<\/strong> in combination therapy<\/li>\n\n\n\n<li><strong>Resistance Management:<\/strong> Shows ability to <strong>overcome drug resistance<\/strong> mechanisms<\/li>\n\n\n\n<li><strong>Broad Applicability:<\/strong> Targets fundamental oncogenic pathway across multiple tumor types<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-preclinical-amp-clinical-data\" class=\"wp-block-heading\">Preclinical &amp; Clinical Data<\/h2>\n\n\n\n<h3 id=\"h-preclinical-profile\" class=\"wp-block-heading\">Preclinical Profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Efficacy:<\/strong> Demonstrated <strong>broad anti-tumor efficacy<\/strong> across multiple models<\/li>\n\n\n\n<li><strong>Potency:<\/strong> <strong>High activity at low doses<\/strong> \u2013 favorable therapeutic index<\/li>\n\n\n\n<li><strong>Safety:<\/strong> <strong>Favorable safety profile<\/strong> with strong ADMET characteristics<\/li>\n\n\n\n<li><strong>Selectivity:<\/strong> Specific targeting of TEAD transcription factors with minimal off-target effects<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-development-status\" class=\"wp-block-heading\">Clinical Development Status<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase I Trial:<\/strong> Global multicenter study initiated January 2025<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Heavily pre-treated mesothelioma patients with limited options<\/li>\n\n\n\n<li><strong>Trial Design:<\/strong> Dose escalation followed by expansion cohorts in specific indications<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Accelerated development supported by FTD and ODD designations<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-strategic-value\" class=\"wp-block-heading\">Market Context &amp; Strategic Value<\/h2>\n\n\n\n<h3 id=\"h-mesothelioma-treatment-landscape\" class=\"wp-block-heading\">Mesothelioma Treatment Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> Malignant pleural mesothelioma remains largely incurable with median survival of 12-18 months<\/li>\n\n\n\n<li><strong>Treatment Gap:<\/strong> Limited effective options after progression on standard immunotherapy and chemotherapy<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Approximately 3,000 new cases annually in the US, with similar burden globally<\/li>\n\n\n\n<li><strong>Commercial Incentives:<\/strong> Orphan drug exclusivity combined with fast track development creates attractive regulatory pathway<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-ai-drug-discovery-validation\" class=\"wp-block-heading\">AI Drug Discovery Validation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform Credibility:<\/strong> ISM6331 represents validation of Insilico&#8217;s end-to-end AI drug discovery capabilities<\/li>\n\n\n\n<li><strong>Investor Confidence:<\/strong> Demonstrates AI can identify novel targets and generate clinical candidates with differentiated profiles<\/li>\n\n\n\n<li><strong>Competitive Advantage:<\/strong> Positions Insilico as leader in AI-discovered oncology therapeutics<\/li>\n\n\n\n<li><strong>Pipeline Implications:<\/strong> Success validates platform for other TEAD-dependent cancers and transcription factor targets<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical development, regulatory designations, and commercial expectations. Actual results may differ due to clinical trial outcomes, regulatory decisions, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072900100_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072900100_c.\"><\/object><a id=\"wp-block-file--media-94ee3780-7d64-4ac7-8ea0-1350e1ee4f35\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072900100_c.pdf\">2026072900100_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072900100_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-94ee3780-7d64-4ac7-8ea0-1350e1ee4f35\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[99,16,4514,164,80],"class_list":["post-70884","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ai","tag-cancer","tag-hkg-3696","tag-insilico-medicine","tag-priority-reviews"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine&#039;s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company&#039;s proprietary artificial intelligence platform, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable malignant pleural mesothelioma who have progressed following anti-PD-1 antibody therapy and platinum-based chemotherapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70884\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine&#039;s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company&#039;s proprietary artificial intelligence platform, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable malignant pleural mesothelioma who have progressed following anti-PD-1 antibody therapy and platinum-based chemotherapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70884\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T10:33:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70884#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70884\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine&#8217;s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma\",\"datePublished\":\"2026-07-29T10:33:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70884\"},\"wordCount\":437,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AI\",\"Cancer\",\"HKG: 3696\",\"Insilico Medicine\",\"Priority reviews\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70884#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70884\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70884\",\"name\":\"Insilico Medicine's AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-29T10:33:08+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company's proprietary artificial intelligence platform, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable malignant pleural mesothelioma who have progressed following anti-PD-1 antibody therapy and platinum-based chemotherapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70884#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70884\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70884#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine&#8217;s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine's AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company's proprietary artificial intelligence platform, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable malignant pleural mesothelioma who have progressed following anti-PD-1 antibody therapy and platinum-based chemotherapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70884","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine's AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma","og_description":"Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company's proprietary artificial intelligence platform, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable malignant pleural mesothelioma who have progressed following anti-PD-1 antibody therapy and platinum-based chemotherapy.","og_url":"https:\/\/flcube.com\/?p=70884","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-29T10:33:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70884#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70884"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine&#8217;s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma","datePublished":"2026-07-29T10:33:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70884"},"wordCount":437,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AI","Cancer","HKG: 3696","Insilico Medicine","Priority reviews"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70884#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70884","url":"https:\/\/flcube.com\/?p=70884","name":"Insilico Medicine's AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-29T10:33:08+00:00","description":"Insilico Medicine (HKG: 3696) announced that ISM6331, a novel pan-TEAD inhibitor discovered through the company's proprietary artificial intelligence platform, has received Fast Track Designation (FTD) from the U.S. Food and Drug Administration (FDA) for treating adult patients with unresectable malignant pleural mesothelioma who have progressed following anti-PD-1 antibody therapy and platinum-based chemotherapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70884#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70884"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70884#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine&#8217;s AI-Discovered Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Malignant Pleural Mesothelioma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70884","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70884"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70884\/revisions"}],"predecessor-version":[{"id":70887,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70884\/revisions\/70887"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}